Avanir Pharmaceuticals, Inc.

8-K

Completion of Acquisition or Disposition of Assets, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Other Events, Financial Statements or Exhibits

01/13/15

8-K

To Be Acquired by Otsuka Pharmaceutical for $3.5 Billion

12/02/14

8-K

Receives Complete Response Letter (CRL) From FDA on AVP-825 NDA

11/28/14

8-K

Change in Directors, Officers or Compensation

11/12/14

8-K

Announces Preliminary Feedback From the FDA on AVP-825 for the Acute Treatment of Migraine

11/07/14

8-K

######## ########## ########## ######### ########## ## ########

09/25/14

8-K

######### ######## ##### ## ##### ####### ### ####### ## ######### ## ######### ## ######## #### ########### #######

09/15/14

Search in Documents

Key Exhibits

External Links

Financials Filter

Prospectuses and Registrations Filter

Ownership Filter

News Filter

Proxies Filter

Other Filter

Avanir Pharmaceuticals, Inc. Watch